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A set of guidelines has been developed for using the peptide hits technique (PHT) as a
semi-quantitative screening tool for the identification of proteins that change in abundance in
a complex mixture. The dataset that formed the basis for these experiments was created using
a cell lysate derived from the yeast Saccharomyces cerevisiae, spiked at various levels with serum
albumin (BSA), and analyzed by LC/MS/MS and SEQUEST. Knowing that the level of only
one protein (BSA) actually changed in the mixture allowed for the development and
refinement of the necessary bioinformatics and statistical analyses, e.g., principal component
analysis (PCA), normalization, and analysis of variation (ANOVA). As expected, the number
of BSA peptide hits changed in proportion to the amount of BSA added to the sample. PCA
was able to clearly distinguish between the spiked samples and the untreated sample,
indicating that PCA may be able to classify samples, e.g., healthy versus diseased, in future
experiments. The use of an endogenous “housekeeping” protein was found to be superior to
the use of total hits for data normalization prior to analysis. An ANOVA based model readily
identified BSA as a protein of interest, that is, one likely to be changing from amongst the
background proteins, indicating that an ANOVA model may be able to identify individual
proteins in target or biomarker discovery experiments. General guidelines based on these
combined observations are set forth for future analyses and the rapid screening for candidate
proteins of interest. (J Am Soc Mass Spectrom 2005, 16, 1231–1238) © 2005 American Society
for Mass SpectrometryThe use of protein biomarkers to detect diseases intheir earliest stages holds the potential to savethousands of lives [1]. The advancement of pro-
teomic techniques has recently led to the discovery of a
series of biomarkers for different disease states [2–6].
While the traditional proteomic method (two-dimen-
sional gel electrophoresis (2D-PAGE) followed by mass
spectrometry) to elucidate differences between normal
and disease-state samples still remains in use, this
technique is not adequately reproducible, labor inten-
sive, and hard to automate [7, 8]. Recent advances in
mass spectrometers and their related informatics plat-
forms, in particular the ion trap mass spectrometer and
the SEQUEST algorithm, were fueled in part by the
development of multidimensional high performance
liquid chromatography (HPLC) techniques [9–12].
However, the lack of quantification in these methods
led to the later development of the isotope coded
affinity tag (ICAT) [13, 14] method and other labeling
techniques (SILAC, GIST, AQUA) [15–17].
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doi:10.1016/j.jasms.2004.12.002While these labeling techniques are being developed
and refined, our laboratory has focused on performing
semi-quantitative proteomics using the peptide hits
technique (PHT). PHT relies on collating and summing
up total number of peptide hits generated from tandem
mass spectrometry data for a particular protein. Earlier
studies in our laboratory indicate that the total number
of peptide hits for a specific protein semi-quantitatively
reflect its abundance in a given protein mixture [5, 18].
Although much less precise than the labeling methods,
this PHT is much easier to implement and therefore less
prone to errors or experimental artifacts. The PHT has
been proven successful in several biomarker and target
discovery programs [2, 3, 5, 19]. Liu et al. and Blondeau
et al. have used a similar concept named spectral
sampling and successfully estimated relative protein
abundance in complex protein mixtures [20–22].
Previous projects using the PHT demonstrated that
statistical tools commonly used for gene array experi-
ments were also applicable to proteomic data [3, 18].
The purpose of the project described here was to refine,
optimize, and guide the application of these bioinfor-
matic techniques by analyzing a well-defined sample.
Therefore, a set of recommendations or guidelines
would be established for performing data analysis on
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where the compositions of the samples would be un-
known or less well-defined. In the present case, differ-
ent known amounts of serum albumin (BSA) were
spiked into a yeast whole cell lysate, digested, run
through LC/MS/MS system, and then searched against
SEQUEST. The data was subsequently analyzed using
PCA to broadly distinguish the spiked samples from
the untreated samples. Various normalization methods
were explored using total peptide hits and “housekeep-
ing” proteins. Finally, an ANOVA based method was




A protease deficient strain of the baker’s yeast
Saccharomyces cerevisiae termed SGY 1276, a Squibb
Genetic Yeast which was derived from the publicly
available strain Y197, was grown in 10 mL volumes of
SD minimal media (Clontech, Palo Alto, CA) at 30 °C.
The culture media was supplemented with uracil, tryp-
tophan, and leucine. The cells were harvested in log
phase (o.d. 1; 1e7 cells per mL) by centrifugation at
1000 g at 4 °C for 30 min. Each pellet was washed with
phosphate buffered saline solution (Sigma, St. Louis,
MO) and lysed in 500 L Y-Per (Pierce, Rockford, IL)
according to the manufacturer’s instructions. The ly-
sates were pooled and protein concentration was deter-
mined by BCA assay [23]. Bovine serum albumin was
obtained (Sigma) and used without further purification.
Proteolysis
The yeast cell lysate was subjected to chloroform meth-
anol protein precipitation and the protein pellet was
brought back into solution with 8 M urea/100 mM
ammonium bicarbonate. To gain statistical power in
future data analysis, triplicate sets of samples were
prepared. For each set of samples, yeast proteins were
split into eight aliquots and different amounts of BSA
were spiked into the various yeast solutions to make
eight protein mixtures with final BSA concentrations of
0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, and 125 ng/L, respec-
tively (These eight conditions would be referred to as
Table 1. Samples information








H 12.50 50.00treatment A, B, C, D, E, F, G, and H). Each treatmentcontained the same concentration of total yeast protein
(1000 ng/L). All the samples were digested as previ-
ously described [18]. Samples were subsequently dia-
lyzed (Dispo-Microdialyzer, 500 Dalton, The Nest
Group, Southborough, MA) against 0.2 % acetic acid for
3 h at room temperature. Samples were stored at 4 °C
before loading onto the LC/MS/MS system.
Automated LC/MS/MS System
Reversed-phase high performance liquid chromatogra-
phy coupled to tandem mass spectrometry was con-
ducted using a microbore column (Zorbax 300 SB-C18,
3 m, 1  150 mm, Agilent, Wilmington, DE). The
autosampler (Famos, Dionex/LC Packings, San
Francisco, CA) was supplied with mobile phase from a
binary pump (Agilent 1100). Each injection made use of
a 50 l loop (The amount of BSA and yeast on the
column for each of the eight treatments was described
in Table 1). The flow rate through the microbore column
was held constant at 50 l/min. The mobile phases
(MP) used were as follows: MPA  0.001% trifluoro-
acetic acid (TFA)  0.1% acetic acid  0.2% 2-propanol
in water, MPB  0.001% TFA  0.1% acetic acid  0.2%
2-propanol  95% acetonitrile in water. The gradient
was 0–2 min, 0–10% MPB; 2–62 min, 10–40% MPB;
62–67 min, 40–100% MPB; 67–70 min, 100% MPB;
70–80 min, 0% MPB.
The effluent from the RPLC column was connected
to an ion trap mass spectrometer (LCQDeca, Thermo-
Electron, San Jose, CA) equipped with a standard
electrospray source. The capillary temperature was set
to 250 °C, and the electrospray voltage was set to 5 kV.
Automatic gain control was switched on with a target
value of 5xe7 for each survey scan which maximum
injection time was 50 ms. For each MS/MS scan, the
Figure 1. Two dimensional representation of the principal com-
ponent analysis (PCA) of all 24 datasets (eight treatments in
triplicate) and 700 protein identifications across 24 datasets. The
X-axis represents PC#1 and the Y-axis represents PC#2. The first
two principal components represent 72.3% of the LC-MS/MS
data. The data clearly shows that replicates of each treatment (A to
H) are readily clustered. There is an overall trend from treatment
A to treatment H (from low BSA spike to high BSA spike) as well.
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of 400 ms. The instrument was set to trigger data
dependent fragmentation of the three most intense ions
during the MS survey scan. A total of 24 data sets were
Figure 2. Representative total ion chromatogr
shown are triplicate samples for treatment D.collected.Data Analysis
The SEQUEST algorithm was applied to each of the
data file sets using the yeast proteome database (YPD,
for replicate samples. The ion chromatogramsamsIncyte, Beverly, MA) plus BSA [24]. No SEQUEST score
1234 GAO ET AL. J Am Soc Mass Spectrom 2005, 16, 1231–1238filters were applied to the data set. For a typical
LC/MS/MS data set, approximately 4500 MSMS spec-
tra were acquired, about 2800 of those were assigned to
peptides. These numbers were reproducible across all
datasets. The total number of protein identifications
was greater than 5700 from the 24 data files which
would include both false positives and false negatives.
The highest scoring SEQUEST peptide hit was used for
each spectrum searched. The 24 data files were com-
piled in a spreadsheet program (Excel, Microsoft,
Redmond, WA). In order to make the dataset more
manageable, proteins were deleted if they were not
observed in at least 6 out of the 24 data files. This
reduced the number of total protein identifications to
700. Data analyses were performed in Partek for PCA,
Student’s t-test and an ANOVA model with Bonferroni
correction (Partek Inc., St. Charles, MO).
Results and Discussion
The data was first subjected to principle component
analysis (PCA). PCA is a method commonly used in
microarray research to draw cursory, broad correlation
between mRNA expression profiles by reducing the
dimensionality of the datasets [25–27]. PCA is designed
to capture the variance in a dataset in terms of its
principle components. In effect, one is trying to reduce
the dimensionality of the data to summarize the most
important (i.e., defining) parts whilst simultaneously
filtering out noise. As the LC/MS/MS dataset repre-
sented here was multi-dimensional, it was beneficial to
perform PCA in order to draw broad correlation among
protein profiles. The PCA matrix consisted of twenty
four datasets (eight treatments consisting of three rep-
licates per treatment) and 700 protein identifications
across the twenty four datasets. After PCA was per-
formed on this 24  700 matrix, the first principal
component represented 68.4% of the data and the
second principal component represented 3.8% (see
Figure 1). The remaining 27.7% of data were distributed
among remaining 21 principal components with no
single principal component representing more than
3.8% of the data. In essence, 70% of the LC-MS/MS
data represented by the first two principal components
of the PCA clearly distinguished the spiked samples
Table 2. Pearson’s correlation coefficient among triplicate data








A 0.97 0.96 0.96
B 0.96 0.96 0.96
C 0.96 0.96 0.95
D 0.96 0.96 0.96
E 0.94 0.95 0.95
F 0.95 0.95 0.95
G 0.94 0.93 0.94
H 0.95 0.94 0.94from the untreated samples. Furthermore, the overalltrend A–H (low BSA spike to high BSA spike) was
captured by PCA as well. This indicates that PCA could
be a rapid data analysis tool to identify broad trends in
protein profiling experiments. It could also be used to
triage samples taken from a broad population in order
to find protein profiles that correlate with treatment,
response, or adverse event. Such analyses could also be
useful to analyze data in order to ensure that the data is
clustered by biological rather than artificial (time of
analysis, date of analysis, analyst, etc.) effects.
Figure 2 represents typical total ion chromatograms
generated during LC/MS/MS analysis from replicate
samples for a specific treatment. It demonstrates qualita-
tive reproducibility for replicate analysis. Additionally,
Pearson correlation coefficients were generated among the
triplicate datasets to study the quantitative reproducibility
of replicate analyses for each treatment. A Pearson corre-
lation coefficient is a dimensionless index that ranges from
1.0 to 1.0 and reflects the extent to which a linear
relationship exists between two data sets. If all the pro-
teins had exactly the same number of peptide hits in each
replicate experiment, the correlation coefficient would be
1.00. For the eight treatments, A, B, C, D, E, F, G, and H,
the correlation coefficients of all replicate analyses were
above 0.90 (Table 2) indicating high overall quantitative
reproducibility.
The following set of analyses focused on the change
in BSA peptide hits as a function of loading. As ex-
Figure 3. The change of peptide hits as a function of loading. (a)
shows as the abundance of BSA increases, the peptide hits
increase. (b) demonstrates peptides hits correlate with BSA level
in a logarithmic fashion.
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amount of BSA in the samples increased, though not in
a 1:1 ratio, but instead in a clear logarithmic relationship
(Figure 3). With the standard curve of R2  0.9784,
experimental peptide hits value can be easily back-
calculated to fold change of the protein. A Student’s
t-test was used to determine if the changes of BSA hits
observed between treatments were significant (P .05).
Among all treatments, hit changes between every two-
fold change in BSA spiking (except treatments B versus
C) were statistically significant (see Table 3). Further-
more, hit changes as small as 16% (treatment D versus
E) could be detected with good probability (P value 
.032). The comparison between B and C did not pass the
Student’s t-test (P value .092), this could be attributed
to the non-linearity of the PHT technique at the lower
protein concentration. However, a fourfold change (be-
tween B and D) in BSA was found to be statistically
significant (P value  .008). The results indicated that if
the change of peptide hits of a protein between two
treatment groups was statistically significant, most
likely the biological change of abundance of the under-
lying protein was at least twofold. This is fortuitous, as
this magnitude of change is that which is typically
discussed when searching for biomarkers or targets [16,
28, 29].
Another set of statistical analysis was imple-
mented to differentiate BSA from the yeast proteins
among the eight treatments, knowing that only BSA
was truly changing across the treatments. An
ANOVA based method with Bonferroni correction
was selected as a method of choice to analyze the








A 0.00 0 2
B 0.20 0 24
C 0.39 2 27
D 0.78 4 43
E 1.56 8 47 
F 3.13 16 68
G 6.25 32 80
H 12.50 64 101
Table 3. (b) Percent change and Student t-test P value of BSA
hits observed between neighboring treatments
Treatments % Hit change
Student’s t-test
P value
B vs. C 7.4% 0.092
C vs. D 35.7% 0.003
D vs. E 16.0% 0.032
E vs. F 21.8% 0.022
F vs. G 28.0% 0.032
G vs. H 13.5% 0.036
*B vs. D 40.50% 0.008*Comparison between B and D was performed because changes
between B and C did not pass the Student’s t-test (P value  .092).data. ANOVA is a powerful statistical method that
can be used to separate and estimate the different
causes of variation while Bonferroni correction ap-
plies a very conservative and rigorous statistical
adjustment for multiple comparisons [30 –32]. The
results showed that 37 out of the 700 proteins passed
the ANOVA with Bonferroni correction test (Table 4).




(sample 3) Average %CV
1 0 1 100.0
27 23 25 8.4
27 26 27 2.2
40 43 42 4.1
51 51 50 4.6
63 62 64 5.0
97 90 89 9.6
104 105 103 2.0
Table 4. Proteins that passed ANOVA with Bonferroni
correction (Bonferroni  P value  700)
Protein ID Bonferroni Pearson
1 P1_228883 1.22E-12 1.00
2 TDH3 3.36E-06 0.94
3 TDH2 6.18E-06 0.94
4 ENO1 8.16E-06 0.90
5 ADH1 9.15E-06 0.92
6 TDH1 1.04E-05 0.94
7 PDC1 1.28E-05 0.92
8 ENO2 1.82E-05 0.92
9 CDC19 3.13E-05 0.93
10 EFT1 6.59E-05 0.89
11 SSB2 1.13E-04 0.90
12 EFT2 2.11E-04 0.88
13 SSB1 2.49E-04 0.90
14 IPP1 2.61E-04 0.85
15 YIL152W 4.97E-04 0.88
16 PGK1 5.46E-04 0.92
17 YNL134C 6.29E-04 0.92
18 CIT1 1.00E-03 0.88
19 MET6 1.29E-03 0.92
20 ARA1 1.40E-03 0.78
21 PGI1 1.51E-03 0.94
22 ACO1 2.20E-03 0.93
23 SSA1 2.29E-03 0.88
24 YHB1 2.73E-03 0.90
25 HXK2 5.58E-03 0.87
26 CYS3 6.32E-03 0.88
27 GND1 7.35E-03 0.92
28 SHM2 1.08E-02 0.72
29 MET17 1.33E-02 0.81
30 PDC6 1.41E-02 0.85
31 HXK1 1.53E-02 0.86
32 TEF1 1.54E-02 0.91
33 TEF2 2.92E-02 0.90
34 SSA2 3.40E-02 0.84
35 ILV5 3.42E-02 0.88
36 SSC1 3.51E-02 0.85its
1)37 UBI4 3.86E-02 0.87
1236 GAO ET AL. J Am Soc Mass Spectrom 2005, 16, 1231–1238significant difference among the experiments accord-
ing to the model, even though only BSA was known
to change. However, among the 37 proteins, BSA had
the lowest P value (Bonferroni  1.22E-012), implying
that it was most likely changing. The other 36 yeast
proteins were false positives. In order to find out if
there was any correlation between the changes of the
36 proteins and BSA loading across all eight treat-
ments. Pearson correlation coefficient was calculated
by comparing peptide hits of each of 36 proteins with
those of BSA. Interestingly, out of the 36 false posi-
tives, 35 yeast proteins were inversely correlated with
changes of BSA. This is probably the result of large
amount of BSA peptides ions competing for fragmen-
tation selection during the survey scans, thus increas-
ing the likelihood of other peptides not being
selected, fragmented, and identified. Figure 4 dem-
onstrated a typical example: the change of average
hits of Eno1 across all eight treatments compared
with that of BSA. However, even though the peptide
hits of Eno1 decreased while hits of BSA increased
from treatment A to treatment H, the change of BSA
(Bonferroni  1.22 E-12) was much more significant
than that of Eno1 (Bonferroni  8.16E-06).
To adjust for the “competition effect” and thereby
reduce the false positives, two normalization (or
scaling) methods that are commonly used in mRNA
expression (transcriptional profiling) data analysis
were explored. The first method scales the mean of
the peptide hit values within a given run by multi-
plying all values by a constant. In this case, the
peptide hits were summed for each individual run,
and these sums were used to determine the run with
the median total peptide hits. This value was then
used as the basis for calculating the peptide hits
multiplier (PHM) for each run (see eq 1).
PHMnTmedian ⁄ Tn (1)
Where PHMn is PHM at treatment n, n  {A, ... ,H}; Tmin
is the median total peptide hits across all the treatment,
and Tn is the total peptide hits at treatment n, n  {A, ...,
H}. The PHM was then used to scale the data in each
Figure 4. Numbers of peptide hits for Eno1 are shown to
inversely correlate with those of BSA showing there is a compet-
ing effect between the two proteins. However, the change of BSA
is more significant.run, and at the end of this calculation, the summed
values of peptide hits for each run were all identical.
This PHM correlates to the Brightness Adjustment
which is typically used for transcriptional profiling data
analysis [33–35]. The same ANOVA model with Bon-
ferrroni correction was applied to the normalized data.
The results showed, 16 proteins out of the 700 total
proteins passed the test, and therefore false positives
were reduced by over 50% (from 36 to 15) through the
scaling process. As in the first analysis, BSA had the
lowest Bonferroni value (Bonferroni  5.07E-012, Table
5).
Another popular normalization method applied in
mRNA expression data analyses uses the intensity of a
“housekeeping” protein (which is supposed to stay
constant throughout treatment regimes) to scale the
intensities of all proteins [36]. In order to reduce the
number of false positives from the current 15 to zero,
Fructose-Biphosphate Aldolase 1 (FBA1) was used to
scale the original data set. This was based on the
assumption that the abundance of FBA1 was, or should
have been, constant across all samples. FBA1 is a fairly
high abundant yeast protein with codon bias value of
0.868 [37], and it did not pass the ANOVA/Bonferroni
test on original dataset. The reasons stated above made
FBA1 a good candidate to perform normalization across
datasets. In order to use FBA1 as a normalization
protein, all the intensity values with each run would
have to be normalized by a constant, so the peptide hits
of FBA1 would be the same cross all the treatments after
normalization (Figure 5a versus Figure 5b). After the
normalization, the same ANOVA/Bonferroni model
was applied and only four proteins showed a statisti-
cally significant difference. BSA once again came out on
top of the list (Bonferroni  8.28E-07, Table 6). Even
though there were still three false positives in the final
data set, the P value with Bonferroni correction was still
more than four orders of magnitude lower than the next
Table 5. Proteins that passed ANOVA with Bonferroni

















16 BNI5 4.47E-02closest protein (YIL152W) which averaged three hits
1237J Am Soc Mass Spectrom 2005, 16, 1231–1238 GUIDELINES FOR PEPTIDE HITS TECHNIQUEacross the samples (Figure 6). Furthermore, error rate of
three false positives out of 700 proteins was only 0.4%,
and the false negative rate was effectively zero. Consid-
ering that the peptide hits technique is both intended to
be, and used as, a simple and rapid whole proteome
screening technique, and that any candidates so discov-
ered will always be validated through at least one
subsequent orthogonal method, such as immunoassay
or AQUA, the error rates associated with this approach
would not be of significant concern.
Conclusions
The PHT continues to mature as a useful technique
for semi-quantitative proteome screening. Peptide
hits were shown to correlate with protein abundance
in a logarithmic fashion while the PCA method was
shown to distinguish patterns of interest in large data
sets. Furthermore, the ANOVA statistical model with
Bonferroni correction was well suited to proteomic
Figure 5. Numbers of peptide hits for FBA1 and BSA are shown
before and after FBA1 normalization.
Table 6. Proteins that passed ANOVA/Bonferroni after data





4 HAP1 1.01E-02data analysis. Two different scaling techniques (total
peptide hits adjustment and an abundant protein
adjustment) were explored and of these, adjustment
based on the use of an abundant protein was found to
generate the lowest rate of false positive identifica-
tions (0.4%) while introducing no false negatives.
On the basis of the analyses shown here, we propose
some general guidelines for future routine analyses
using the peptide hits technique: design experiments to
incorporate duplicate or even triplicate measurements
(depending on sample source); prepare all samples in
exactly the same way, at exactly the same time, and
preferably by the same person in order to maximize
reproducibility and minimize artifacts; screen initial
data set by PCA to ensure that there are no underlying
issues with the data set, e.g., time of day, day of week,
analyst, instrument effects, etc. and that the treatment
effect is dominant. Based on the data presented in this
manuscript, PHT does well across a dynamic range of
about two orders of magnitude. Therefore, a twofold
change in protein abundance can be readily detectable
using the PHT. Many of the current biostatistical tools
such as PCA, ANOVA, t-test, as well as other vigorous
statistical analyses are amenable to protein profiling
and can serve to reduce the number of false positives.
Furthermore, as in any profiling technique, once a list of
protein candidates is generated, follow-on experiments
must be performed to confirm the results and eliminate
false positives.
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